Skin barrier strength and wound return after diabetic foot ulcers heal
Studies whether healed diabetic foot ulcers with past biofilm infection come back more often.
Key facts
- Who runs it
- University of Pittsburgh
- Where
- Cranberry Township and Tucson, United StatesSee the 2 sites
- Trial code
- Registry title
- Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence
- Status
- Recruiting
- People taking part
- 405 people, planned
- Started
- 2 Apr 2024
- Expected to end
- 27 Jun 2029
- Type of study
- Observational
- Record updated
- 18 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an open diabetic foot ulcer. It studies whether ulcers with a past biofilm infection heal with a weaker skin barrier and come back more often.
- Age
- 18 years and older
- Sex
- All sexes
- Disease stage
- An open diabetic foot ulcer. For wounds below the knee, blood flow to the leg must be good enough, shown by at least one test: TcOM >30 mmHg, ankle-brachial index at least ≥0.7, toe pressure > 30 mmHg, or TBI > 0.6 mmHg.
- Earlier treatment
- People whose wound was closed, or will be closed, by surgery with a skin flap or graft cannot join.
- Biomarker or test result
- Hemoglobin A1c must not be above 15 within 3 months before joining. TcOM must not be < 30mmHg.
Main reasons for not taking part
- A clearly weak immune system, such as HIV/AIDS or taking medicines that suppress the immune system
- Autoimmune connective tissue disease
- Ulcer size or place that does not allow the skin water loss (TEWL) measurement
- Pregnant women or prisoners
- Not able to understand the study or to follow study visits and procedures
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Male or Female, Age ≥ 18
- Willing to comply with protocol instructions, including all study visits and study activities
- Patient with an open Diabetic Foot Ulcer
- Adequate arterial blood flow as evidenced by at least one of the following (for wounds below the knee):
- TcOM >30 mmHg
- Ankle-brachial index at least ≥0.7
- Toe pressure > 30 mmHg
- TBI > 0.6 mmHg
Who cannot take part
- Subjects with marked immunodeficiency (HIV/AIDS, or on immunosuppressive medications
- Subject with autoimmune connective tissue disease
- Ulcer size and location that does not allow the TEWL measurement per SOP
- Diabetics with a hemoglobin A1c > 15 within 3 months prior to enrollment
- Individuals who are deemed unable to understand the procedures, risks, and benefits of the study
- Wounds closed or to be surgically closed by flap or graft coverage
- TcOM < 30mmHg
- Pregnant women
- Prisoners
- Unable to comply with study procedures and/or complete study visits
Where in United States
- UPMC Wound Healing Services at UPMC PassavantCranberry Township, United StatesContact: Chandan K Sen, Phd (principal investigator)Taking people
- University of ArizonaTucson, United StatesContact: Fleur MaturoTaking people
About the trial
What the trial wants to find out
This work is based on DFU patients, seeks to conduct a fully powered clinical study testing i) If DFU with a history of biofilm infection closes with deficient barrier function. ii) whether such functionally deficient wound closure, manifested as high TEWL, is associated with greater wound recurrence. The primary parent study will also address molecular mechanisms implicated in biofilm-induced loss of skin epithelial barrier integrity in DFU patients.
The group in the trial
- Diabetic Foot Ulcer study
405 clinically diagnosed Diabetic Foot Ulcer (DFU) patients who are suspected to be infected will be recruited . Wound swab for culture obtained. Baseline digital imaging of target wound(s). SF-12 Health survey, Visual Analogue Pain scale, Cardiff wound impact questionnaires. Wound site evaluation including TcOM/TBI/ankle brachial index (ABI) will be completed for subjects with wounds below the knee, if not already completed per standard of care within the previous 12 months. Hemoglobin A1c point of care testing will be drawn for diabetic subjects who do not have an A1c available within 90 days prior to enrollment; 3mm biopsy tissue or debrided tissue will be collected. Ideally, two tissue samples will be obtained; the subject's medical records will be reviewed and followed for up to 16 weeks or until their wound has closed, whichever comes first. The research staff will also call the patient or care facility as needed to check for wound closure.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence
- Plain-language title
- Skin barrier strength and wound return after diabetic foot ulcers healGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 18 March 2026